 ALX Oncology Holdings Inc NASDAQ: ALXO presented initial clinical data from its ongoing Phase 1 2 trial evaluating evorpacept combined with azacitidine for untreated higher-risk or relapsed or refractory myelodysplastic syndrome. The new results were shared at the 63rd American Society of Hematology ASH. 